These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 12649353

  • 1. Pharmacological characterization of a novel nonpeptide antagonist radioligand, (+/-)-N-[2-methyl-4-methoxyphenyl]-1-(1-(methoxymethyl) propyl)-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine ([3H]SN003) for corticotropin-releasing factor1 receptors.
    Zhang G, Huang N, Li YW, Qi X, Marshall AP, Yan XX, Hill G, Rominger C, Prakash SR, Bakthavatchalam R, Rominger DH, Gilligan PJ, Zaczek R.
    J Pharmacol Exp Ther; 2003 Apr; 305(1):57-69. PubMed ID: 12649353
    [Abstract] [Full Text] [Related]

  • 2. 125I-Tyro-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2 alpha receptors.
    Grigoriadis DE, Liu XJ, Vaughn J, Palmer SF, True CD, Vale WW, Ling N, De Souza EB.
    Mol Pharmacol; 1996 Sep; 50(3):679-86. PubMed ID: 8794910
    [Abstract] [Full Text] [Related]

  • 3. [(3)H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors.
    Varani K, Merighi S, Gessi S, Klotz KN, Leung E, Baraldi PG, Cacciari B, Romagnoli R, Spalluto G, Borea PA.
    Mol Pharmacol; 2000 May; 57(5):968-75. PubMed ID: 10779381
    [Abstract] [Full Text] [Related]

  • 4. [¹²⁵I]YP20: a novel radioligand specific for the extracellular domain of the CRF₁ receptor.
    Gordon JC, Edwards P, Elmore CS, Lazor LA, Paschetto K, Bostwick R, Sylvester M, Mauger R, Scott C, Aharony D.
    Eur J Pharmacol; 2010 Dec 15; 649(1-3):59-63. PubMed ID: 20854803
    [Abstract] [Full Text] [Related]

  • 5. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001.
    Okuyama S, Chaki S, Kawashima N, Suzuki Y, Ogawa S, Nakazato A, Kumagai T, Okubo T, Tomisawa K.
    J Pharmacol Exp Ther; 1999 May 15; 289(2):926-35. PubMed ID: 10215672
    [Abstract] [Full Text] [Related]

  • 6. Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of corticotropin-releasing factor receptors.
    Perrin MH, Sutton SW, Cervini LA, Rivier JE, Vale WW.
    J Pharmacol Exp Ther; 1999 Feb 15; 288(2):729-34. PubMed ID: 9918582
    [Abstract] [Full Text] [Related]

  • 7. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.
    Hoare SR, Sullivan SK, Schwarz DA, Ling N, Vale WW, Crowe PD, Grigoriadis DE.
    Biochemistry; 2004 Apr 06; 43(13):3996-4011. PubMed ID: 15049707
    [Abstract] [Full Text] [Related]

  • 8. Rational design, synthesis, and structure-activity relationships of aryltriazoles as novel corticotropin-releasing factor-1 receptor antagonists.
    Lowe RF, Nelson J, Dang TN, Crowe PD, Pahuja A, McCarthy JR, Grigoriadis DE, Conlon P, Saunders J, Chen C, Szabo T, Chen TK, Bozigian H.
    J Med Chem; 2005 Mar 10; 48(5):1540-9. PubMed ID: 15743196
    [Abstract] [Full Text] [Related]

  • 9. Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.
    Chen C, Wilcoxen KM, Huang CQ, Xie YF, McCarthy JR, Webb TR, Zhu YF, Saunders J, Liu XJ, Chen TK, Bozigian H, Grigoriadis DE.
    J Med Chem; 2004 Sep 09; 47(19):4787-98. PubMed ID: 15341493
    [Abstract] [Full Text] [Related]

  • 10. Different binding modes of amphibian and human corticotropin-releasing factor type 1 and type 2 receptors: evidence for evolutionary differences.
    Dautzenberg FM, Py-Lang G, Higelin J, Fischer C, Wright MB, Huber G.
    J Pharmacol Exp Ther; 2001 Jan 09; 296(1):113-20. PubMed ID: 11123370
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Potent, orally active corticotropin-releasing factor receptor-1 antagonists containing a tricyclic pyrrolopyridine or pyrazolopyridine core.
    Dyck B, Grigoriadis DE, Gross RS, Guo Z, Haddach M, Marinkovic D, McCarthy JR, Moorjani M, Regan CF, Saunders J, Schwaebe MK, Szabo T, Williams JP, Zhang X, Bozigian H, Chen TK.
    J Med Chem; 2005 Jun 16; 48(12):4100-10. PubMed ID: 15943483
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Binding differences of human and amphibian corticotropin-releasing factor type 1 (CRF(1)) receptors: identification of amino acids mediating high-affinity astressin binding and functional antagonism.
    Dautzenberg FM, Wille S.
    Regul Pept; 2004 May 15; 118(3):165-73. PubMed ID: 15003833
    [Abstract] [Full Text] [Related]

  • 16. Peptide ligand binding properties of the corticotropin-releasing factor (CRF) type 2 receptor: pharmacology of endogenously expressed receptors, G-protein-coupling sensitivity and determinants of CRF2 receptor selectivity.
    Hoare SR, Sullivan SK, Fan J, Khongsaly K, Grigoriadis DE.
    Peptides; 2005 Mar 15; 26(3):457-70. PubMed ID: 15652653
    [Abstract] [Full Text] [Related]

  • 17. Monkey corticotropin-releasing factor1 receptor: Complementary DNA cloning and pharmacological characterization.
    Oshida Y, Ikeda Y, Chaki S, Okuyama S.
    Life Sci; 2004 Feb 27; 74(15):1911-24. PubMed ID: 14761672
    [Abstract] [Full Text] [Related]

  • 18. Corticotropin-releasing factor receptors in human small cell lung carcinoma cells: radioligand binding, second messenger, and northern blot analysis data.
    Dieterich KD, Grigoriadis DE, De Souza EB.
    Endocrinology; 1994 Oct 27; 135(4):1551-8. PubMed ID: 7925116
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Receptor occupancy of nonpeptide corticotropin-releasing factor 1 antagonist DMP696: correlation with drug exposure and anxiolytic efficacy.
    Li YW, Hill G, Wong H, Kelly N, Ward K, Pierdomenico M, Ren S, Gilligan P, Grossman S, Trainor G, Taub R, McElroy J, Zazcek R.
    J Pharmacol Exp Ther; 2003 Apr 27; 305(1):86-96. PubMed ID: 12649356
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.